Wanbury Limited
Valuation (83/100) does the heavy lifting; financial trend (0/100) is the drag.
Buy zoneStocksWizard rates Wanbury Limited a Sell, scoring 43/100 on our blended model. At ₹293.55 it trades below our blended DCF and relative-multiples fair value of ₹587.1, about 100% upside to that estimate — we read it as undervalued by 100%. On 14.4x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 15% below its 52-week high of ₹344.75 and 80% above the low of ₹163.34. It clears 4 of 8 investability checks, with durability 8, valuation 65 and momentum 79 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹469.68. Low-confidence estimate — limited data.
1-year price
EOD · 2026-07-3152-week range
-14.85% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell43Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- No data: ROE above 15%
- No data: Low debt (D/E < 0.5)
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: -19%
- No data: Earnings growing
- Fail: Net margin ≥ 10%: -25.9%
- No data: Current ratio > 1.5
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- No data: Altman Z in safe zone
- Fail: Piotroski ≥ 7: 3/9
Shareholding
- Promoter51.2%
- Institutions2.1%
- Public & other46.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Opportunities
- Trading in our value buy zone versus sector peers.
- Trades ~100% below our estimated fair value.
Bear case
Weaknesses
- Weak Piotroski score (3/9).
About Wanbury Limited
Wanbury Limited manufactures and distributes pharmaceutical formulations and active pharmaceutical ingredients across India and international markets. Its formulation portfolio spans anti-infectives, pain management, respiratory, gastroenterology, gynecology, rheumatology, central nervous system disorders, and nutritional products. The company also produces APIs for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medications.
Wanbury Limited — frequently asked questions
Is Wanbury Limited a buy, hold or sell?
StocksWizard currently rates Wanbury Limited (WANBURY) a Sell, based on a blended score of 43/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Wanbury Limited's fair value?
Our blended DCF and relative-valuation model estimates Wanbury Limited's fair value at about ₹587.1, versus a current price of ₹293.55 — roughly 100% upside. On that basis the stock looks undervalued by 100%.
How has Wanbury Limited's share price performed?
Wanbury Limited is up 17% over three months, and last traded at ₹293.55. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.